Resources


  • Kayentis supports the 1st personalized immunotherapy treatment approved by both FDA & CHMP
    9 July 2019

    Acute Lymphoblastic or Lymphoid Leukemia (ALL) is a… | Read More

  • Press release // OMRON Healthcare and Kayentis join forces to deliver an integrated and cost-efficient approach to remote monitoring of patients in clinical trials
    25 October 2018

    We are proud to announce our collaborative work… | Read More

  • Kayentis & RWS Life Sciences Partnering for Success – Global Immunology & Dermatology Phase II Study
    4 September 2018

    Kayentis & RWS Life Sciences – Case Study… | Read More

  • Pediatric Case Study: Global Phase II – Children and Young Adults
    19 July 2018

    Global Phase II study – Children and Young… | Read More

  • Case study oncology Kayentis
    Oncology Case Study: Global Phase III Oncology Study – Melanoma
    17 January 2018

    With its strong experience in eCOA market, Kayentis… | Read More

  • Case study dermatology Kayentis
    Dermatology case study: Global Phase III Studies – Psoriasis
    12 January 2018

    After a case study about autoimmune, inflammatory & skin… | Read More

  • case study ecoa experience
    Dermatology & autoimmune case study: an extensive eCOA experience in autoimmune, inflammatory and skin diseases
    2 January 2018

    Kayentis has a strong eCOA experience in autoimmune,… | Read More

  • wearable devices
    Mobile technologies & wearable devices for Healthcare and Clinical Research
    27 November 2017

    Mobile technology & wearable devices are becoming increasingly… | Read More

  • Case study cardiovascular Kayentis
    Cardiovascular case study: Global Phase III Study – Heart Failure & Actigraphy
    18 May 2017

    After case studies about autoimmune & skin diseases, psoriasis… | Read More

  • Actigraphy devices: a real impact on clinical research?
    3 May 2017

    Actigraphy has been used in clinical trials for… | Read More

  • Infography: planning an oncology study with eCOA/ePRO
    21 February 2017

    The FDA has provided guidance on methodology to… | Read More

  • eCOA solutions oncology
    eCOA solutions in oncology: What to consider when planning an oncology study with eCOA /ePRO?
    13 December 2016

    The FDA has provided guidance on methodology to… | Read More

  • tablet device for eCOA
    Key benefits of using a “Tablet device” for eCOA in Psoriasis studies
    2 September 2016

    Psoriasis is a chronic immune-mediated inflammatory disease of… | Read More

Agenda

  • 06 May
    OCT Europe 2020 - May 6-7 - Paris, France - Booth #83 - Schedule a meeting with Kayentis
  • 14 June
    DIA 2020 - June 14-18 - Washington, DC - Booth #239 - Schedule a meeting with Kayentis
  • Follow us

    Download our brochure